Recent years have seen a surge of interest in the use of covalent compounds in small molecule drug discovery. Much of this interest has been driven by the success of covalent compounds for “undruggable” targets such as kRAS. While it is relatively easy to buy or build a library of cysteine reactive compounds and screen them using mass spectrometry (MS), does this really provide all the information to decide whether a “hit” is a good starting point for a drug discovery campaign?
Typically, a covalent campaign starts with screening a library for conjugation…
32nd Protein Structure Determination in Industry meeting
In person Starting from Sunday, November 10th, the ZoBio team participated in the 32nd Protein Structure Determination in Industry meeting, which was held at the Novotel Paris Centre Tour Eiffel in Paris, France. This year’s meeting was organized jointly by SERVIER and Synchrotron SOLEIL, with support from Hg3 Conferences. The scientific talks focused on the…
Discovery on Target
In person Our team participated in Discovery on Target, the industry’s preeminent event on novel drug targets and technologies for drug discovery professionals. The conference highlighted advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents, ranging from biologics to small…
SCI / RSC 22nd Medicinal Chemistry Symposium
In person From 10 to 13 September the ZoBio team participated in SCI/RSC 22nd Medicinal Symposium in Cambridge. This symposium, is Europe’s premier biennial Medicinal Chemistry event, focusing on first disclosures and new strategies in Medicinal Chemistry. ZoBio was represented by Denise Tsagris, Henri van Son and Kasia Borsuk. It was a great opportunity to…